MX2010000474A - Inhibidores de proteina serina/treonina quinasa a/proteina quinasa b con actividad antitumoral. - Google Patents

Inhibidores de proteina serina/treonina quinasa a/proteina quinasa b con actividad antitumoral.

Info

Publication number
MX2010000474A
MX2010000474A MX2010000474A MX2010000474A MX2010000474A MX 2010000474 A MX2010000474 A MX 2010000474A MX 2010000474 A MX2010000474 A MX 2010000474A MX 2010000474 A MX2010000474 A MX 2010000474A MX 2010000474 A MX2010000474 A MX 2010000474A
Authority
MX
Mexico
Prior art keywords
akt
compound
subject invention
cell
pkb
Prior art date
Application number
MX2010000474A
Other languages
English (en)
Inventor
Said M Sebti
Jin Q Cheng
Mei Sun
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Publication of MX2010000474A publication Critical patent/MX2010000474A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Abstract

La invención se refiere a materiales y métodos para inhibir la vía Akt/PKB; en una modalidad, un compuesto de la invención inhibe la actividad de quinasa y/o los niveles de fosforilación de las proteínas Akt; la invención también se refiere a métodos para inhibir o eliminar una célula cancerosa u otra célula en la que la expresión de una proteína Akt esta elevada o constitutivamente activa, que comprende poner en contacto la célula con una cantidad efectiva de un compuesto de fórmula I; la invención también se refiere a métodos para tratar cáncer o un tumor en una persona o animal que comprende administrar una cantidad efectiva de un compuesto de fórmula I a la persona o animal.
MX2010000474A 2007-07-12 2008-07-14 Inhibidores de proteina serina/treonina quinasa a/proteina quinasa b con actividad antitumoral. MX2010000474A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94936507P 2007-07-12 2007-07-12
PCT/US2008/069974 WO2009009793A2 (en) 2007-07-12 2008-07-14 Inhibitors of akt/pkb with anti-tumor activity

Publications (1)

Publication Number Publication Date
MX2010000474A true MX2010000474A (es) 2010-06-23

Family

ID=40229514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000474A MX2010000474A (es) 2007-07-12 2008-07-14 Inhibidores de proteina serina/treonina quinasa a/proteina quinasa b con actividad antitumoral.

Country Status (10)

Country Link
US (2) US8183249B2 (es)
EP (1) EP2173352B1 (es)
JP (1) JP5568471B2 (es)
KR (1) KR101618037B1 (es)
CN (1) CN101743007B (es)
AU (1) AU2008274956B2 (es)
BR (1) BRPI0815563A2 (es)
CA (1) CA2695330C (es)
MX (1) MX2010000474A (es)
WO (1) WO2009009793A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2576765C (en) * 2004-09-03 2013-05-28 Applied Research Systems Ars Holding N.V. Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
US8183249B2 (en) * 2007-07-12 2012-05-22 University Of South Florida Inhibitors of AKT/PKB with anti-tumor activity
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ,インコーポレイテッド ジケトピペラジンを用いた医薬組成物
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
WO2012158197A2 (en) * 2010-11-11 2012-11-22 Lyndor Biosciences L.L.C. Compounds useful as akt/pkb modulators and uses thereof
MX348655B (es) * 2011-04-01 2017-06-21 Genentech Inc Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer.
CA2831935A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
CN102225067B (zh) * 2011-04-29 2012-10-03 济南环肽医药科技有限公司 一种治疗胃癌的药物组合物
SG10201608087WA (en) 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
ES2795803T3 (es) 2011-10-10 2020-11-24 Ampio Pharmaceuticals Inc Tratamiento de artropatía degenerativa
AU2012328605B9 (en) 2011-10-28 2017-08-03 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
GB201207722D0 (en) * 2012-05-02 2012-06-13 Bergenbio As Method
KR101461626B1 (ko) * 2012-08-02 2014-11-28 서울대학교산학협력단 Akt1 억제제 및 소수성 항암제를 포함하는 항암용 약학적 조성물
WO2014074883A1 (en) * 2012-11-08 2014-05-15 Lyndor Biosciences L.L.C. Novel synthesis of ld101
EA201500943A1 (ru) 2013-03-15 2016-08-31 Ампио Фармасьютикалс, Инк. Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов
US9974774B2 (en) 2013-07-26 2018-05-22 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
US9986375B2 (en) * 2014-02-12 2018-05-29 Google Llc Energy-efficient location determination
US9956217B2 (en) 2014-08-18 2018-05-01 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
FR3033499A1 (fr) * 2015-03-11 2016-09-16 Centre Leon-Berard Composition pour le traitement des tumeurs neuroendocrines pancreatiques
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW MOLECULAR WEIGHT HUMAN SERUM ALBUMIN FRACTIONS FOR TREATING DISEASES
CN114099681B (zh) * 2020-12-04 2023-03-10 周清华 Akt/stat3作为免疫检查点抑制剂的靶点的用途
WO2023168291A1 (en) * 2022-03-02 2023-09-07 Terremoto Biosciences, Inc. Covalent modifiers of akt1 and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP4407008B2 (ja) * 2000-05-11 2010-02-03 パナソニック株式会社 カラー画像形成装置
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
BR0309581A (pt) * 2002-05-06 2005-03-29 Genelabs Tech Inc Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
AU2005228410A1 (en) * 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US8828451B2 (en) * 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
US8183249B2 (en) * 2007-07-12 2012-05-22 University Of South Florida Inhibitors of AKT/PKB with anti-tumor activity

Also Published As

Publication number Publication date
JP2010533206A (ja) 2010-10-21
EP2173352A2 (en) 2010-04-14
US20090028855A1 (en) 2009-01-29
CA2695330A1 (en) 2009-01-15
KR20100066438A (ko) 2010-06-17
WO2009009793A2 (en) 2009-01-15
CA2695330C (en) 2017-06-13
WO2009009793A3 (en) 2009-03-26
EP2173352A4 (en) 2011-07-27
CN101743007A (zh) 2010-06-16
BRPI0815563A2 (pt) 2015-02-18
KR101618037B1 (ko) 2016-05-04
JP5568471B2 (ja) 2014-08-06
EP2173352B1 (en) 2016-09-07
AU2008274956A1 (en) 2009-01-15
US20130034598A1 (en) 2013-02-07
AU2008274956B2 (en) 2014-08-21
US8183249B2 (en) 2012-05-22
US9359347B2 (en) 2016-06-07
CN101743007B (zh) 2015-04-08

Similar Documents

Publication Publication Date Title
MX2010000474A (es) Inhibidores de proteina serina/treonina quinasa a/proteina quinasa b con actividad antitumoral.
PH12020500203A1 (en) Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors
EA201100119A1 (ru) Химические соединения 251
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
MX2009009304A (es) Inhibidores de cinasa pim y metodos para su uso.
ATE525375T1 (de) Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
MY148246A (en) Bicyclic amides as kinase inhibitors
TW200801008A (en) Protein kinase inhibitors
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
MY152948A (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
ECSP055911A (es) Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
EA201070611A1 (ru) Ингибиторы человеческой фосфатидилинозитол-3-киназы дельта
MY148468A (en) Compounds and methods for kinase modulation, and indications therefor
MX2009006688A (es) Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
IL192557A (en) Imidazole derivatives are conserved and used as ptpase inhibitors
MX2013012661A (es) Compuestos de piridazina biciclicos como inhibidores pim.
MX2012012031A (es) Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
MX2021008667A (es) Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo.

Legal Events

Date Code Title Description
FG Grant or registration